

INFORMATION DISCLOSURE STATEMENT (37 CFR 1.56, 1.97, and 1.98) SHEET 1 OF 1				ATTORNEY DOCKET 37522-1002		APPLICATION NO. 09/910,461	
				APPLICANT(S) Peter D. Gluckman, et al.			
				INTERNATIONAL FILING DATE July 20, 2001		GROUP 1639 1627	
US PATENT DOCUMENTS							
† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	NAME		CLASS/ SUBCLASS	FILING DATE (If appropriate)
FOREIGN PATENT DOCUMENTS							
† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	COUNTRY		TRANSLATION (YES/NO)	
<i>ML</i>	B1	0 366 638	10/24/89	EPO		Yes	
<i>ML</i>	B2	WO 95/17204	07/29/95	PCT		Yes	
<i>ML</i>	B3	WO 98/14202	04/09/98	PCT		Yes	
OTHER DOCUMENTS							
† EX'R INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)					
<i>ML</i>	C1	V. Sara, et al, "Identification of GLY-PRO-GLU (GPE), The Aminoterminal Tripeptide Of Insulin-Like Growth Factor 1 Which Is Truncated In Brain, As A Novel Neuroactive Peptide", Biochemical & Biophysical Research Communications vol. 165, no. 2, 1989, December 15, 1989 pp 766-771.					
<i>ML</i>	C2	L. Nilsson-Hakansson, et al., "Effects of IGF-1, Truncated IGF-1 And The Tripeptide Gly-Pro-Glu On Acetylcholine Release From Parietal Cortex Of Rat Brain", Neuroreport, 4,1111-1114(1993)					
<i>ML</i>	C3	J. Saura, "Neuroprotective Effects Of Gly-Pro-Glu, the N-terminal Tripeptide Of IGF-1, In The Hippocampus In Vitro", Neuroreport Vol. 10, pp. 161-164 (1999).					
<i>ML</i>	C4	V. Sara, "The Biological Role of Truncated Insulin-Like Growth Factor-1 and The Tripeptide GPE In The Central Nervous System", Annals of the New York Academy of Sciences vol. 692, pp 183-191 (1998)					
EXAMINER'S SIGNATURE <i>B CELSA</i>				DATE CONSIDERED <i>4/9/03</i>			
† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. Include copy of this form in next communication to applicant.							
* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 USC 120. 37 CFR 1.98(d).							